生血宁片预防非小细胞肺癌患者化疗外周血细胞下降的临床观察

目的探讨生血宁片联合NP方案化疗非小细胞肺癌对预防外周血细胞下降的疗效。方法将72例非小细胞肺癌（non-smallcell lung cancer，NSCLC）患者随机分为治疗组和对照组，治疗组（37例）采用生血宁片加NP方案治疗，对照组（35例）采用NP方案化疗。观察两者外周血常规变化及集落刺激因子用量。结果生血宁治疗4周后，治疗组较对照组白细胞、血小板计数升高升高，差异有统计学意义（P〈0．05）；治疗组外周血WBC、PLT、HB治疗后与治疗前差异无统计学意义（P〉0＂05）；对照组外周血WBC、PLT、HB治疗后较治疗前下降，其中WBC、PLT差异有统计学意义（P〈0.05）；对照纽G—CSF用量高于治疗组（P〈0．05）；治疗组生存改善率优于对照组，两组差异有统计学意义（P〈0．05）。结论生血宁片可预防预防非小细胞肺癌患者NP方案化疗的骨髓抑制作用并改善病人的生存质量，值得推广。

Objective： To evaluate the effect of shengxuening tablet on the blood cell count of NSCLC patients with chemotherapy. Methods： The patients were randomized into two groups： the treatment group consisted of 37 patients treated with a combination of shengxuening tablet and NP chemotherapy, the control group comprised 35 patients treated with NP chemotherapy.The patients were evaluated to white blood cell （WBC）, hemoglobin （HB） and blood plates （PLT）, Karnofsky score as well as drug dose ofrhG-CSF （re-combinant human granulocyte colony stimulating factor）. Results ： The means of WBC and PLT of the patients after 4 weeks in treatment group is higher than the means of the patients in the control group , and there was a significant difference between them （P〈0.05）. There was a statistical difference between the used dose ofrhG-CSF in two groups （P〈0.05） . The karnofsky score of the treatment group is higher than the control group, and there was a significant difference between them （P〈0.05）. Conclusions： Shengxuening tablet may be effective to prevent myelosuppression and raise WBC and PLT of the NSCLC patients treated with NP chemotherapy, improve the quality of the life of the patients.